Inhibition by pentoxifylline of TNF-α-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-κB down-regulation

Authors

  • Yung-Ming Chen,

    1. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
    Search for more papers by this author
  • Chao-Jung Tu,

    1. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
    Search for more papers by this author
  • Kung-Yu Hung,

    1. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
    Search for more papers by this author
  • Kwan-Dun Wu,

    1. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
    Search for more papers by this author
  • Tun-Jun Tsai,

    1. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
    Search for more papers by this author
  • Bor-Shen Hsieh

    Corresponding author
    1. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, Taipei, Taiwan
    Search for more papers by this author

Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 10016, Taiwan; E-mail: bshsieh@ha.mc.ntu.edu.tw

Abstract

  • Fractalkine is a CX3C chemokine for mononuclear leukocytes that is expressed mainly by vascular cells, and regulated by pro-inflammatory cytokines. This study investigated signal transduction mechanisms by which tumor necrosis factor (TNF)-α stimulated fractalkine expression in cultured rat vascular smooth muscle cells (VSMCs), and the modulatory effect of a haemorrheologic agent, pentoxifylline, on its production.

  • TNF-α (1–50 ng ml−1) stimulated fractalkine mRNA and protein expression in concentration- and time-dependent manners. Pretreatment with calphostin C (0.4 μM, a selective inhibitor of protein kinase C (PKC), and PD98059 (40 μM), a specific inhibitor of p42/44 mitogen-activated protein kinase (MAPK) kinase, attenuated TNF-α-stimulated fractalkine mRNA and protein expression. In contrast, H-89 (2 μM), a selective inhibitor of cAMP-dependent protein kinase, wortmannin (0.5 μM), a selective inhibitor of phosphatidylinositol 3-kinase, and SB203580 (40 μM), a specific inhibitor of p38 MAPK, had no discernible effect.

  • The ubiquitin/proteosome inhibitors, MG132 (10 μM) and pyrrolidine dithiocarbamate (200 μM), suppressed activation of NF-κB as well as stimulation of fractalkine mRNA and protein expression by TNF-α.

  • TNF-α-activated phosphorylation of PKC was blocked by calphostin C, whereas TNF-α-augmented phospho-p42/44 MAPK and phospho-c-Jun levels were reduced by PD98059. Neither calphostin C nor PD98059 affected TNF-α-induced degradation of I-κBα or p65 nuclear translocation.

  • Pretreatment with pentoxifylline (0.1–1 mg ml−1) decreased TNF-α-stimulated fractalkine mRNA and protein expression, which was preceded by a reduction in TNF-α-activated phosphorylation of PKC, p42/44 MAPK and c-Jun as well as degradation of I-κBα and p65/NF-κB nuclear translocation.

  • These data indicate that activation of PKC, p42/44 MAPK kinase, and NF-κB are involved in TNF-α-stimulated fractalkine production in VSMCs. Down-regulation of the PKC, p42/44 MAPK, and p65/NF-κB signals by PTX may be therapeutically relevant and provide an explanation for the anti-fractalkine effect of this drug.

British Journal of Pharmacology (2003) 138, 950–958. doi:10.1038/sj.bjp.0705088

Ancillary